Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
, 23 (1), 365-75

Selective Serotonin Reuptake Inhibitor Treatment and Risk of Fractures: A Meta-Analysis of Cohort and Case-Control Studies

Affiliations
Meta-Analysis

Selective Serotonin Reuptake Inhibitor Treatment and Risk of Fractures: A Meta-Analysis of Cohort and Case-Control Studies

Q Wu et al. Osteoporos Int.

Abstract

Studies on use of selective serotonin reuptake inhibitors (SSRIs) and risk of fracture have yielded inconsistent results. This meta-analysis, which pooled results from 13 qualifying cohort and case-control studies, found that SSRIs were associated with a significantly increased risk of fractures.

Introduction: This study was conducted to assess whether people who take SSRIs are at an increased risk of fracture.

Methods: We conducted a meta-analysis of observational studies. Relevant studies published by February 2010 were identified through literature searches using MEDLINE (from 1966), EMBASE (from 1988), PsycINFO (from 1806), and manual searching of reference lists. Only cohort or case-control studies that examined the association of SSRIs and risk of fracture and bone loss were included. Data were abstracted independently by two investigators using a standardized protocol; disagreements were resolved by consensus. Random effects models were used for pooled analysis due to heterogeneity in the studies.

Results: Thirteen studies met inclusion criteria. Overall, SSRI use was associated with a significantly increased risk of fracture (relative risk, RR, 1.72; 95% CI [1.51, 1.95]; P < 0.001). An increased fracture risk associated with SSRIs also was observed in the three studies that adjusted for bone mineral density (RR, 1.70; 95% CI [1.28, 2.25]; P < 0.001) and in the four studies that adjusted for depression (RR 1.74; 95% CI [1.28, 2.36]; P < 0.001). SSRI use was not associated with bone loss in the two cohort studies of women (P = 0.29). The overall association between SSRI use and fracture risk was weaker (RR, 1.40; 95% CI [1.22, 1.61]), though still significant (P < 0.001) in analyses that accounted for apparent publication bias.

Conclusions: Use of SSRIs is associated with increased risk of fracture. The SSRIs may exert an increased risk of fracture independent of depression and bone mineral density.

Comment in

Similar articles

See all similar articles

Cited by 41 PubMed Central articles

See all "Cited by" articles

References

    1. Med Hypotheses. 2001 Oct;57(4):469-71 - PubMed
    1. Am J Epidemiol. 2003 Jul 1;158(1):77-84 - PubMed
    1. Prim Care Companion J Clin Psychiatry. 2003 Aug;5(4):153-157 - PubMed
    1. Ann Pharmacother. 2009 Jan;43(1):98-103 - PubMed
    1. Stat Med. 2002 Jun 15;21(11):1539-58 - PubMed

Publication types

Substances

Feedback